NAS10029,709+0.19%S&P7,737+0.19%GOLD$4,053−0.54%BTC$80,942+0.17%VIX17.29−1.31%latest tape · as of 18:04 UTC
The Screen · Technology · Information Technology Services
Genpact Limited
G · the NYSE · USD · Market cap $6.5B · 145,000 employees
Genpact Limited provides business process outsourcing and information technology services in India, the rest of Asia, North and Latin America, and Europe.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.18, read 2026-10-27
Ethical passes the values gate
Price39.20 USD
Fair value53.75
Ethical score64.7/100
Our investment reviews on this name
2026-10-11Read Markup34.70+13.0% to today ✓Distribution gives way to Markup first Markup read since August
2026-10-02Read Distribution34.70+13.0% to today Markup gives way to Distribution after a 12% rise in 9 weeks
2026-07-30Read Markup30.89+26.9% to today ✓Distribution gives way to Markup after a 5% slide in 4 weeks
2026-07-02Read Distribution32.62+20.2% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Genpact Limited holds its Markup at $39.20. Consolidating, no directional conviction, held for 6 days.
As held on the ledger · 2026-10-27
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 6 days
Price at the screen
$39.20
Valuation
11.52 trailing · 8.58 forward price to earnings
Values screen
PASS· score 64.7
Beta
0.58
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
30.20%
Below 33%
Interest-bearing debt is just 30.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
5.99%
Below 33%
Cash held in interest-bearing accounts and securities is 6.0% of assets, under the one-third limit.
Pass
Receivables
35.84%
Below 49%
Money owed to the company is 35.8% of assets, under the 49% limit.
Pass
Revenue purity
0.47%
Below 5%
Only 0.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Genpact clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 30%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when G's ethical verdict changes
Today G passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-27 screen. The gold marker is the market price at the same screen. A 38.9% margin of safety to the base estimate.
Third-party analyst targets: 11 covering, consensus Buy. The average target sits +10% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Outsourcing engine runs on thin growth margins
Picture a big bank or retailer sending its back-office drudgery, from loan processing to customer queries, to teams spread across India and beyond. That steady flow of work is Genpact's core, split across financial services, consumer healthcare and manufacturing clients.
The shares trade at 6.9 times forward earnings with an 11 percent profit margin and 23 percent return on equity, sitting 58 percent below our fair value. Revenue growth of just 7 percent keeps the opportunity rating at none, however, even though the ethical screen clears and analysts lean buy with a 39 dollar median target.
An unknown competitive moat leaves room for larger rivals to steal share, while currency swings and modest top-line momentum cap any real re-rating. The low multiple reflects that reality rather than a bargain.
The risks · The things to watch: its business and earnings are exposed to Bermuda and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
G trades on the NYSE (the company is based in Bermuda). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-25Markup$38.70+3.0%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $42.
2026-10-18Markup$37.59+8.3%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $42.
2026-10-11Markup · changed$34.70+0.0%Entry 7
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $42.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $42.
2026-08-30Markup$37.25+20.6%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 20.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $42.
2026-07-30Markup · changed$30.89-5.3%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 5.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $42.
2026-07-18Distribution$32.62+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 26%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it buy, with a mean price target of $42.
2026-07-03Distribution$32.62+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (65). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$32.62Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (65). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
